Biocartis Group NV
XBRU:BCART

Watchlist Manager
Biocartis Group NV Logo
Biocartis Group NV
XBRU:BCART
Watchlist
Price: 0.29 EUR
Market Cap: 27.2m EUR
Have any thoughts about
Biocartis Group NV?
Write Note

Intrinsic Value

The intrinsic value of one BCART stock under the Base Case scenario is 0.95 EUR. Compared to the current market price of 0.29 EUR, Biocartis Group NV is Undervalued by 69%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

BCART Intrinsic Value
0.95 EUR
Undervaluation 69%
Intrinsic Value
Price
Base Case Scenario

Valuation Backtest
Biocartis Group NV

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for BCART cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about BCART?
Bearish
Neutral
Bullish

Fundamental Analysis

Risks & Rewards

 

 

 

 

View All Risks & Rewards
Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Notes
AI Assistant
AI Assistant
Ask me anything about Biocartis Group NV

Provide an overview of the primary business activities
of Biocartis Group NV.

What unique competitive advantages
does Biocartis Group NV hold over its rivals?

What risks and challenges
does Biocartis Group NV face in the near future?

Has there been any significant insider trading activity
in Biocartis Group NV recently?

Summarize the latest earnings call
of Biocartis Group NV.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Biocartis Group NV.

Provide P/S
for Biocartis Group NV.

Provide P/E
for Biocartis Group NV.

Provide P/OCF
for Biocartis Group NV.

Provide P/FCFE
for Biocartis Group NV.

Provide P/B
for Biocartis Group NV.

Provide EV/S
for Biocartis Group NV.

Provide EV/GP
for Biocartis Group NV.

Provide EV/EBITDA
for Biocartis Group NV.

Provide EV/EBIT
for Biocartis Group NV.

Provide EV/OCF
for Biocartis Group NV.

Provide EV/FCFF
for Biocartis Group NV.

Provide EV/IC
for Biocartis Group NV.

What are the Revenue projections
for Biocartis Group NV?

How accurate were the past Revenue estimates
for Biocartis Group NV?

What are the Net Income projections
for Biocartis Group NV?

How accurate were the past Net Income estimates
for Biocartis Group NV?

What are the EPS projections
for Biocartis Group NV?

How accurate were the past EPS estimates
for Biocartis Group NV?

What are the EBIT projections
for Biocartis Group NV?

How accurate were the past EBIT estimates
for Biocartis Group NV?

Compare the revenue forecasts
for Biocartis Group NV with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Biocartis Group NV and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Biocartis Group NV against its competitors.

Analyze the profit margins
(gross, operating, and net) of Biocartis Group NV compared to its peers.

Compare the P/E ratios
of Biocartis Group NV against its peers.

Discuss the investment returns and shareholder value creation
comparing Biocartis Group NV with its peers.

Analyze the financial leverage
of Biocartis Group NV compared to its main competitors.

Show all profitability ratios
for Biocartis Group NV.

Provide ROE
for Biocartis Group NV.

Provide ROA
for Biocartis Group NV.

Provide ROIC
for Biocartis Group NV.

Provide ROCE
for Biocartis Group NV.

Provide Gross Margin
for Biocartis Group NV.

Provide Operating Margin
for Biocartis Group NV.

Provide Net Margin
for Biocartis Group NV.

Provide FCF Margin
for Biocartis Group NV.

Show all solvency ratios
for Biocartis Group NV.

Provide D/E Ratio
for Biocartis Group NV.

Provide D/A Ratio
for Biocartis Group NV.

Provide Interest Coverage Ratio
for Biocartis Group NV.

Provide Altman Z-Score Ratio
for Biocartis Group NV.

Provide Quick Ratio
for Biocartis Group NV.

Provide Current Ratio
for Biocartis Group NV.

Provide Cash Ratio
for Biocartis Group NV.

What is the historical Revenue growth
over the last 5 years for Biocartis Group NV?

What is the historical Net Income growth
over the last 5 years for Biocartis Group NV?

What is the current Free Cash Flow
of Biocartis Group NV?

Discuss the annual earnings per share (EPS)
trend over the past five years for Biocartis Group NV.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Biocartis Group NV

Current Assets 69.9m
Cash & Short-Term Investments 24.9m
Receivables 18.9m
Other Current Assets 26.1m
Non-Current Assets 44.3m
Long-Term Investments 6.2m
PP&E 31.5m
Intangibles 4.8m
Other Non-Current Assets 1.9m
Current Liabilities 42.4m
Accounts Payable 11.7m
Other Current Liabilities 30.7m
Non-Current Liabilities 102.1m
Long-Term Debt 101.8m
Other Non-Current Liabilities 353k
Efficiency

Earnings Waterfall
Biocartis Group NV

Revenue
60.6m EUR
Cost of Revenue
-29.5m EUR
Gross Profit
31.2m EUR
Operating Expenses
-74.3m EUR
Operating Income
-43.2m EUR
Other Expenses
-24.7m EUR
Net Income
-67.9m EUR

Free Cash Flow Analysis
Biocartis Group NV

Last Value
3-Years Average
FCF Margin
Conversion Rate
Fundamental Scores

BCART Profitability Score
Profitability Due Diligence

Biocartis Group NV's profitability score is 35/100. The higher the profitability score, the more profitable the company is.

Exceptional ROE
Positive Gross Profit
ROE is Increasing
Positive 3-Years Revenue Growth
35/100
Profitability
Score

Biocartis Group NV's profitability score is 35/100. The higher the profitability score, the more profitable the company is.

BCART Solvency Score
Solvency Due Diligence

Biocartis Group NV's solvency score is 32/100. The higher the solvency score, the more solvent the company is.

Low D/E
Short-Term Solvency
Long-Term Solvency
Positive Net Debt
32/100
Solvency
Score

Biocartis Group NV's solvency score is 32/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

BCART Price Targets Summary
Biocartis Group NV

There are no price targets for BCART.
Lowest
Price Target
Not Available
Average
Price Target
Not Available
Highest
Price Target
Not Available
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for BCART?

Click here to dive deeper.

Dividends

Biocartis Group NV
does not pay dividends
Shareholder Yield

Current shareholder yield for BCART is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Ownership

BCART Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Profile

Biocartis Group NV Logo
Biocartis Group NV

Country

Belgium

Industry

Health Care

Market Cap

27m EUR

Dividend Yield

0%

Description

Biocartis Group NV which engages in the development of oncology molecular diagnostic solutions. The company is headquartered in Malines (Mechelen), Antwerpen and currently employs 619 full-time employees. The company went IPO on 2015-04-27. The group has the Idylla system to deliver results within a period of between 35 to 150 minutes.

Contact

ANTWERPEN
MALINES (MECHELEN)
Generaal de Wittelaan 11B
+3215632600.0
biocartis.com

IPO

2015-04-27

Employees

619

Officers

Chief Operating Officer
Mr. Piet Houwen
Chief Executive Officer
Mr. Roger Moody
CFO & Head of Service Delivery
Mr. George A. Cardoza
Chief Technology Officer
Mr. Benoit Devogelaere
Chairman of Scientific Advisory Board & Chief Scientific Officer
Mr. Geert Maertens Ph.D.
Head of IR & Corporate Communications
Renate Degrave
Show More
Senior Vice-President of Corporate Development and Strategy
Mr. Erik Vossenaar Ph.D.
Head of People & Organization
Ms. Susy Spruyt
Head of R&D and Alliance Management
Dr. Erwin Sablon
Head of Manufacturing & Supply Chain
Mr. Reginald Van Genechten
Show Less

See Also

Discover More
What is the Intrinsic Value of one BCART stock?

The intrinsic value of one BCART stock under the Base Case scenario is 0.95 EUR.

Is BCART stock undervalued or overvalued?

Compared to the current market price of 0.29 EUR, Biocartis Group NV is Undervalued by 69%.

Back to Top